Drug
Ly3819253
Ly3819253: highest development phase Phase 3, developed by Eli Lilly, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eli Lilly, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY3819253 NCT04501978 | Phase 3 | Covid19 |
| LY3819253 NCT04427501 | Phase 2/3 | COVID-19 |
| LY3819253 NCT04411628 | Phase 1 | COVID-19 |
Latest
No recent events.
Follow Ly3819253 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.